Ceftriaxone-Induced Hemolytic Anemia: A Rare and Fatal Reaction

Ceftriaxone, a regularly used antibiotic for broad-spectrum coverage, is a rare cause of hemolytic anemia. Patients may present with truncal pain, nausea, vomiting, and an acute drop in hemoglobin within 48 hours of administration. Prompt recognition and initiation of treatment are essential. We des...

Full description

Saved in:
Bibliographic Details
Published inCurēus (Palo Alto, CA) Vol. 16; no. 5; p. e59646
Main Authors Dicaro, Michael V, Chen, Claire, Wang, Shawn, Eom, Annette Y, Wahi-Gururaj, Sandhya
Format Journal Article
LanguageEnglish
Published United States Cureus Inc 04.05.2024
Cureus
Subjects
Allergy/Immunology
Amputation
Anemia
Antibiotics
Antibodies
Case reports
Foot diseases
Hemoglobin
Hospitals
Hypoxia
Infectious Disease
Internal Medicine
Kidney diseases
Mortality
Nausea
Patients
Respiratory failure
Trends
Ventilators
Vomiting
id critical care
critical care
infectious disease medicine
medical icu
pharmacology
hemolytic anemia
Online AccessGet full text

Cover

More Information
Summary:Ceftriaxone, a regularly used antibiotic for broad-spectrum coverage, is a rare cause of hemolytic anemia. Patients may present with truncal pain, nausea, vomiting, and an acute drop in hemoglobin within 48 hours of administration. Prompt recognition and initiation of treatment are essential. We describe a case of a 65-year-old woman being treated for osteomyelitis who developed hemolytic anemia, disseminated intravascular coagulation, and multi-system organ failure after being de-escalated from cefepime to ceftriaxone.
ISSN:2168-8184
2168-8184
DOI:10.7759/cureus.59646